A phase 1 trial of Senolytic immunotherapy - Immorta Bio (SenoVax) in patients with advanced non-small cell lung cancer

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 24 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Dec 2024 According to an Immorta Bio media release, company has filed an Investigational New Drug (IND) application for SenoVax and anticipates initiating clinical trials in the coming months.
26 Jul 2024 According to an Immorta Bio media release, company announced the filing of an Investigational New Drug (IND) application with the Food and Drug Administration (FDA). The IND was granted to initiate a clinical trial to evaluate safety, immunogenicity, and efficacy signals of SenoVax in patients with advanced non-small cell lung cancer.
26 Jul 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com